Abstract

DO.01.04

Combined intravitreal Triple therapy in retinal vein occlusion – results of a pilot study

Sener A.¹, Koss M. J.², Naser H.², Al Sarireh F.², Singh P.², Scholtz S.², Koch F.^2
1Artemis MVZ Dillenburg; ²Abteilung für Netzhaut- und Glaskörperchirurgie, Universitäts-Augenklinik der Johann-Wolfgang-Goethe-Universität, Frankfurt am Main

Objective: We present a retrospective case series to report the effect of combined intravitreal triple therapy for the treatment of macular edema secondary to central (CRVO) and branch retinal vein occlusion (BRVO).
Methods: 47 patients (mean age 67; 21 women), were divided in ischemic CRVO( group1; n=15); non- ischemic CRVO (group2; n=7) and BRVO (group3; n= 25). All groups received a 23 gauge cppV (sutureless, single sclerotomy) with aspiration of 0.5ml vitreous and substitution of 0.8 mg triamcinolone and 1.25mg bevacizumab through two different openings in one probe tip with an integrated cutter (300cuts p/min). Main outcome measures included BCVA (6m Snellen), IOP (Goldmann applanation tonometry) and central macular thickness (OCT).The monitoring of further treatment was defined as secondary outcome measure.
Results: F/u was 12, 24 and 50 weeks after initial retreatment. At the last f/u, BCVA showed a gain in group 1of 0.07 lines, and a gain of 0.28 lines in group 2 and group 3, respectively. All patients, except of 3/15 (20%, group 1) and 2/25 (8%, group 3) showed significant macular edema resolution in the OCT. IOP rise was measured in 5/47 cases (11%) and controlled with eye drops.
Conclusions: TT indicates promising prelimary results concerning VA and ME resolution mainly in the non-ischemic CRVO and BRVO group. These results might be positively influenced by the pharmacologic synergism and the oxgen redistribution after the cppV.

Copyright: Porstmann Kongresse GmbH. All rights reserved. Impressum, Disclaimer.